Cedars-Sinai investigators have discovered how the liver defends itself against cancer. Their study, published in the peer-reviewed Journal of Hepatology, suggests targets for therapies to protect the liver both from cancers that originate there and cancers that spread to the liver from other parts of the body.
A study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center found that Black men diagnosed with more advanced stages of prostate cancer are significantly less likely to be prescribed novel hormone therapy than other racial and ethnic groups—including white or Latino men—despite the therapy being proven to effectively control the growth of prostate tumors and extend the lives of men with the disease.
A report suggests that Lung-MAP, which for almost a decade has undergirded the first NCI-sponsored precision medicine clinical trial in lung cancer, can serve as a model for future clinical research that is more rapid, innovative, and inclusive.
A study of the relationship between the enzyme DDX5, liver cancer and sorafenib, published in the Nature journal Cell Death & Disease points to the potential for a more effective therapy that combines existing anti-cancer drugs with treatments that spur production of this enzyme.
Researchers have developed a method to predict early on which patients with breast cancer are most likely to stop taking potentially life-saving aromatase inhibitor drugs.
FDA has received reports of T-cell malignancies, including chimeric antigen receptor CAR-positive lymphoma, in patients who received treatment with BCMA- or CD19-directed autologous CAR T-cell immunotherapies.
A planned interim efficacy analysis of the DREAMM-7 head-to-head phase III trial evaluating Blenrep (belantamab mafodotin) as a second-line treatment for relapsed or refractory multiple myeloma produced positive headline results.
How easy is it for a woman to get a mammogram? The answer depends on whether she lives in an urban or a rural area, and it can vary widely based on the racial makeup of her community, according to a study co-authored by researchers from ChristianaCare’s Helen F. Graham Cancer Center & Research Institute and published in Breast Cancer Research.
Combining a pair of experimental drugs may help treat malignant peripheral nerve sheath tumors with fewer harmful side effects, according to preliminary animal studies led by investigators at the Johns Hopkins Kimmel Cancer Center and Johns Hopkins Drug Discovery.
Colorectal cancer screening rates are similar among older adults despite varying 10-year mortality risks, UT Southwestern Medical Center researchers report in a study. The findings, published in The American Journal of Gastroenterology, challenge conventional age-based recommendations for CRC screening that don’t take into account factors like individual life expectancies and comorbidities.
